Showing results (61-70 of 132) with videos related to
Sort By:
Pageof 14
The Journal of Antimicrobial Chemotherapy|December 21, 2004
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)Chloe Orkin, Justin Stebbing, Mark Nelson, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 10, 2011
A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathyDavid B Clifford, David M Simpson, Stephen Brown, et al.Current HIV Research|October 25, 2016
Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled TrialJoel Gallant, Graeme Moyle, Juan Berenguer, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2009
Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1Graeme Moyle, Edwin DeJesus, Marta Boffito, et al.Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.Antimicrobial Agents and Chemotherapy|May 22, 2013
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokineticsGraeme Moyle, Laura Else, Akil Jackson, et al.AIDS (London, England)|June 26, 2007
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistanceMarta Boffito, Alan Winston, Akil Jackson, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal diseaseMelanie Hart, Alan Steel, Sally A Clark, et al.Antiviral Therapy|January 30, 2003
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapyOle Kirk, Court Pedersen, Matthew Law, et al.The Journal of Antimicrobial Chemotherapy|February 4, 2020
Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokineticsEmilie R Elliot, Megan Neary, Laura Else, et al.Pageof 14